Muthiah Vaduganathan
Overview
Explore the profile of Muthiah Vaduganathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
742
Citations
12681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johansen N, Bhatt A, Claggett B, Dueger E, Solomon S, Vaduganathan M, et al.
JAMA Netw Open
. 2025 Mar;
8(3):e250320.
PMID: 40053354
No abstract available.
2.
Inciardi R, Lu H, Claggett B, Desai A, Jhund P, Lam C, et al.
JACC Heart Fail
. 2025 Mar;
PMID: 40047763
Background: Patients with severe heart failure (HF) experience debilitating clinical symptoms and worse cardiovascular (CV) outcomes with an excess mortality risk. Objectives: The authors aimed to assess the prevalence, CV...
3.
McDowell K, Docherty K, Campbell R, Henderson A, Jhund P, Claggett B, et al.
JAMA Cardiol
. 2025 Mar;
PMID: 40042880
Importance: Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) have a spectrum of risk, and the effect of therapies may vary by...
4.
Yang M, Kondo T, Dewan P, Desai A, Lam C, Lefkowitz M, et al.
Circ Heart Fail
. 2025 Mar;
:e011598.
PMID: 40026147
Background: How different combinations of comorbidities influence risk at the patient level and population level in patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction...
5.
Ostrominski J, Claggett B, Miao Z, Filippatos G, Desai A, Jhund P, et al.
Diabetes Care
. 2025 Feb;
PMID: 40019856
Objective: To evaluate the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in individuals with type 2 diabetes (T2D) and either chronic kidney disease (CKD) or heart failure...
6.
Cunningham J, Chatur S, Claggett B, Vaduganathan M, Desai A, Jhund P, et al.
JAMA Cardiol
. 2025 Feb;
PMID: 40009358
Importance: Worsening heart failure (HF) is commonly managed in the outpatient setting with adjustments in oral diuretic therapy. The effect of the nonsteroidal mineralocorticoid receptor antagonist finerenone on outpatient worsening...
7.
Chatur S, Seth M, Casey M, Thompson M, Thompson M, Qureshi M, et al.
Am Heart J
. 2025 Feb;
285:12-20.
PMID: 39988205
Background: Despite the robust clinical evidence base supporting their role for high-risk patients with type 2 diabetes (T2DM) and concomitant cardiovascular disease, prescription of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like...
8.
Agarwal R, Green J, Heerspink H, Mann J, McGill J, Mottl A, et al.
Nephrol Dial Transplant
. 2025 Feb;
PMID: 39916475
Background And Hypothesis: Finerenone, a selective nonsteroidal MRA, and SGLT2is both reduce CKD progression and improve kidney/CV outcomes. The CONFIDENCE study (NCT05254002; EudraCT 2021-003037-11) hypothesis is that early combination of...
9.
Ostrominski J, Plutzky J, Sattar N, Vaduganathan M, Aroda V
Eur J Prev Cardiol
. 2025 Feb;
PMID: 39911097
No abstract available.
10.
Myhre P, Vaduganathan M
J Am Coll Cardiol
. 2025 Feb;
85(5):501-503.
PMID: 39909680
No abstract available.